D.E. Shaw & Co
QNCX icon

D.E. Shaw & Co’s Quince Therapeutics QNCX Stock Holding History

D.E. Shaw & Co’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,588
Closed -$705K – 5462
2022
Q2 		$705K Buy
1,588
+383
+32% +$271K ﹤0.01% 3849
2022
Q1 		$1.49M Buy
1,205
+98
+9% +$133K ﹤0.01% 3581
2021
Q4 		$2.79M Buy
1,107
+1,027
+1,284% +$6.27M ﹤0.01% 3039
2021
Q3 		$1.47M Buy
80
+57
+248% +$907K ﹤0.01% 3293
2021
Q2 		$239K Buy
+23
New +$193K ﹤0.01% 4388
2020
Q4 		– Sell
-65
Closed -$646K – 4120
2020
Q3 		$646K Sell
65
-76
-54% -$691K ﹤0.01% 3096
2020
Q2 		$1.3M Buy
141
+75
+114% +$687K ﹤0.01% 2744
2020
Q1 		$601K Buy
+66
New +$651K ﹤0.01% 3107

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

D.E. Shaw & Co's QNCX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 1,588 shares — an estimated $705K sold.

D.E. Shaw & Co first reported a position in QNCX in Q1 2020 and held it in 8 quarters. The position peaked at $2.79M in Q4 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,588 Quince Therapeutics shares in Q3 2022, an estimated $705K.
  • D.E. Shaw & Co first reported a position in Quince Therapeutics in Q1 2020 and held it in 8 quarters.
  • D.E. Shaw & Co's Quince Therapeutics position peaked at $2.79M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.